Sarepta Therapeutics (SRPT) FY2020 results: revenue $540 million, up 41.8% on the year
Sarepta Therapeutics, Inc. (SRPT) reported revenue of $540 million for fiscal 2020, the year ended 31 December 2020, up 41.8% on the year before. Net income was -$554 million, and diluted earnings per share $-7.11. The figures are the company's own, from the 10-K it filed with the SEC on 1 March 2021.
Revenue
$540 million
+41.8% on the year
FY2014FY2020
Operating margin
-104.5%
-185.3% a year earlier
FY2014FY2020
Net income
-$554 million
FY2014FY2020
Diluted EPS
-$7.11
FY2014FY2020
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2020
FY2019
FY2018
On the year
Last 8 years
Revenue
540
381
301
+41.8%
Research and development
722
561
402
+28.8%
Selling, general and administrative
318
285
208
+11.6%
Operating income
-564
-706
-344
Operating margin
-104.5%
-185.3%
-114.1%
Interest expense
59.9
30.7
33.7
+95.5%
Pre-tax income
-553
-714
-363
Income tax
1.1
1.2
-0.7
-11.0%
Net income
-554
-715
-362
Net margin
-102.6%
-187.8%
-120.2%
Diluted EPS
-$7.11
-$9.71
-$5.46
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2020
FY2019
FY2018
On the year
Last 8 years
Operating cash flow
107
-456
-389
Capital expenditure
82.2
59.6
61.2
+37.9%
Free cash flow
25.3
-516
-450
Free cash flow margin
4.7%
-135.5%
-149.4%
Cash from investing
-122
287
-370
Cash from financing
682
643
530
+6.2%
Depreciation and amortisation
26.9
24.5
12.2
+9.8%
Share-based compensation
108
78.6
50.1
+37.5%
Diluted shares, weighted
78m
74m
66m
+5.9%
Shares outstanding at period end
79m
75m
71m
+5.6%
Balance sheet
$ million
FY2020
FY2019
FY2018
On the year
Last 8 years
Shareholders' equity
762
818
1,032
-6.9%
Debt
992
682
421
+45.5%
Operating lease liabilities
80.4
47.7
n/a
+68.4%
Other liabilities
1,150
275
189
+318.2%
Total liabilities and equity
2,985
1,823
1,642
+63.7%
Fixed assets
190
130
97.0
+46.9%
Intangible assets
13.6
12.5
11.6
+9.1%
Investments
436
290
803
+50.5%
Cash and equivalents
1,503
835
371
+79.9%
Receivables
101
90.9
49.0
+11.5%
Inventory
232
171
125
+35.3%
Other assets
509
294
185
+73.2%
Total assets
2,985
1,823
1,642
+63.7%
10-K for the year ended 31 December 2020, filed 1 March 2021: the filing.